Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement

Area of Science:

• Medical Oncology
• Thoracic Surgery
• Radiation Oncology

Background:

• The optimal treatment for stage IIIA (N2) non-small cell lung cancer (NSCLC) is controversial.
• Neoadjuvant chemotherapy or chemoradiotherapy are feasible induction strategies.
• Mediastinal nodal response after induction therapy predicts survival; residual disease is a negative prognostic factor.

Purpose of the Study:

• To review the current landscape and ongoing research in the multimodality treatment of stage IIIA (N2) NSCLC.
• To highlight the importance of patient selection for surgical resection after induction therapy.
• To discuss future directions in optimizing treatment for this heterogeneous disease stage.

Main Methods:

• Review of existing studies on neoadjuvant chemotherapy and chemoradiotherapy for stage IIIA NSCLC.
• Discussion of patient selection criteria for surgery post-induction therapy.
• Overview of ongoing clinical trials investigating novel induction regimens, surgical approaches, and targeted therapies.

Main Results:

• Lobectomy is generally safe after induction therapy; pneumonectomy may have high perioperative mortality.
• Combined modality therapy has improved overall survival for stage III NSCLC.
• Ongoing trials are exploring various chemotherapy regimens, chemoradiotherapy combinations, and targeted agents.

Conclusions:

• Multimodality treatment, including neoadjuvant therapy and surgery, is crucial for stage III NSCLC.
• Careful patient selection and investigation of novel treatment strategies are essential for improving outcomes.
• Future research focusing on different induction regimens and targeted agents will refine optimal treatment approaches.